Investor updates

Roche’s Hemlibra reduced treated bleeds by 96 percent compared to no prophylaxis in phase III HAVEN 3 study in haemophilia A without factor VIII inhibitors

Roche today announced full results from the phase III HAVEN 3 study evaluating Hemlibra® (emicizumab) prophylaxis administered every week or every two weeks in people with haemophilia A without ...

Reminder: Invitation to Roche’s Virtual Pipeline Event from WFH 2018 World Congress

We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Wednesday, 23 May 2018, from the World Federation of Hemophilia (WFH) 2018 World Congress ...

Follow-up phase III data showed Roche’s Alecensa helped people with ALK-positive metastatic non-small cell lung cancer live a median of almost three years without their disease worsening or death

Roche today announced follow-up data from the phase III ALEX study, showing that, as an initial treatment, Alecensa® (alectinib) significantly reduced the risk of disease progression or death ...

Phase III IMpower150 study showed Roche’s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly longer compared to Avastin plus carboplatin and paclitaxel

Roche today announced positive results from the Phase III IMpower150 study of Tecentriq® (atezolizumab) and Avastin® (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) for the initial ...

FDA approves subcutaneous formulation of Actemra for use in active polyarticular juvenile idiopathic arthritis (pJIA), a rare form of juvenile arthritis

Roche announced today that the US Food and Drug Administration (FDA) has approved the subcutaneous (SC) formulation of Actemra® (tocilizumab) for the treatment of active polyarticular juvenile ...

Roche to present new phase III data for Hemlibra in people with haemophilia A at the World Federation of Hemophilia 2018 World Congress

Roche today announced that phase III results for Hemlibra® (emicizumab) will be presented for the first time during the World Federation of Hemophilia (WFH) 2018 World Congress from 20-24 May in ...

Invitation to Roche’s Virtual Pipeline Event from WFH 2018 World Congress

We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Wednesday, 23 May 2018, from the World Federation of Hemophilia (WFH) 2018 World Congress ...

Roche provides update on Phase III study of Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal cancer

Roche today announced that the Phase III IMblaze370 study evaluating the combination of Tecentriq® (atezolizumab) and Cotellic® (cobimetinib) did not meet its primary endpoint of overall survival ...

Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Roche today announced that new data from its early and late-stage clinical studies, on more than 19 approved and investigational cancer medicines, will be presented at the 2018 American Society of ...

FDA grants priority review to Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer

Roche today announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® ...

CHMP recommends EU approval of Roche’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence

Roche today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Perjeta® (pertuzumab) in combination with Herceptin® ...

Roche reports a strong start in 2018

Group sales increase 6% at constant exchange rates and 5% in Swiss francs. Pharmaceuticals Division sales up 7%, driven mainly by Ocrevus and Perjeta. Diagnostics Division sales grow 5%, with ...

Invitation to Roche Analyst Event at ASCO 2018

We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group’s oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in ...

New OCREVUS (ocrelizumab) data at AAN demonstrate significant reductions in disease activity and disability progression in relapsing multiple sclerosis

Roche announced today that new OCREVUS (ocrelizumab) data were presented at the 70th American Academy of Neurology (AAN) Annual Meeting from 21-27 April in Los Angeles, California.

Reminder: Invitation to Roche’s First Quarter Sales 2018 Audio Webcast and Conference Call

Roche will publish its Sales Results for the 1st Quarter of 2018 prior to the opening of the Swiss Stock Exchange on Thursday April 26th, 2018.

Launch of Tecentriq in 2L+ NSCLC in Japan

FDA grants Breakthrough Therapy Designation for Roche’s Hemlibra in haemophilia A without inhibitors

Roche today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Hemlibra® (emicizumab-kxwh) for people with haemophilia A without factor VIII ...

Roche to present new data at AAN highlighting extensive research for OCREVUS and expanding neuroscience pipeline

Roche announced today that new data on its approved and investigational medicines for neurological conditions will be presented during the 70th American Academy of Neurology (AAN) Annual Meeting from ...

Roche to present data on TECENTRIQ (Atezolizumab) and data from across its cancer immunotherapy portfolio at the 2018 American Association of Cancer Research (AACR) Annual Meeting

Roche today announced that it will present data from across its broad cancer immunotherapy development programme, including approved and investigational medicines, during the American Association for ...

Roche completes acquisition of Flatiron Health

Roche today announced that it has completed the acquisition of Flatiron Health, a privately held healthcare technology and services company headquartered in New York City, US. Flatiron Health is a ...

Roche announces Japanese court ruled in favour of Chugai in Hemlibra patent litigation

Roche today announced that a Japanese court (Tokyo District Court) ruled in favour of Chugai Pharmaceutical Co., Ltd, a member of the Roche Group, in the patent litigation case relating to Hemlibra® ...

Invitation to Roche’s First Quarter Sales 2018 Audio Webcast and Conference Call

Roche will publish its Sales Results for the 1st Quarter of 2018 prior to the opening of the Swiss Stock Exchange on Thursday April 26th, 2018.

Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel

Roche today announced that the Phase III IMpower150 study met its co-primary endpoint of overall survival (OS) at this interim analysis and showed that initial (first-line) treatment with the ...

FDA approves Lucentis (ranibizumab injection) 0.3 mg prefilled syringe for diabetic macular edema and diabetic retinopathy

Roche today announced that the U.S. Food and Drug Administration (FDA) approved the Lucentis® (ranibizumab injection) 0.3 mg prefilled syringe (PFS) as a new method of administering the medicine to ...

Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer

Roche today announced that the Phase III IMpower131 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ (atezolizumab) plus ...

Save the date: Roche Analyst Event at ASCO 2018

We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group’s oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in ...

Roche Annual General Meeting 2018

Roche announced today that its shareholders approved all proposals of the Board of Directors at its ordinary Annual General Meeting (AGM).

Changes to the Roche Enlarged Corporate Executive Committee

Roche today announced that John C. Reed (1958), MD, PhD, Head of Roche Pharma Research and Early Development (pRED) since 2013, has decided to leave Roche for personal reasons and will return to the ...

European Commission approves Roche's Hemlibra for people with haemophilia A with inhibitors

Roche today announced that the European Commission has approved Hemlibra® (emicizumab) for routine prophylaxis of bleeding episodes in people with haemophilia A with factor VIII inhibitors.

Roche to acquire Flatiron Health to accelerate industry-wide development and delivery of breakthrough medicines for patients with cancer

Roche and Flatiron Health, Inc. announced today that the two partners have signed a definitive agreement under which Roche will acquire all shares of Flatiron Health, following on from an existing ...

FDA grants priority review for Roche’s MabThera/ Rituxan (rituximab) for pemphigus vulgaris

Roche announced today that the US Food and Drug Administration (FDA) has accepted the company’s Supplemental Biologics License Application (sBLA) and granted Priority Review for the use of ...

Phase II data support potential for Roche’s novel anti-VEGF/anti-angiopoietin-2 bispecific antibody, RG7716, for people with diabetic macular edema

Roche today announced encouraging results from the Phase II BOULEVARD study.

Roche purchases shares in tender offer for Ignyta, Inc.

Roche and Ignyta, Inc. today announced that Roche’s wholly owned subsidiary Abingdon Acquisition Corp., has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its ...

Reminder: Invitation to Roche's Virtual Pipeline Event

We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Tuesday, 13 February 2018.

Phase III IMmotion151 study showed Roche's TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer

Roche today announced results from the positive Phase III IMmotion151 study of TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) as a first-line treatment for advanced or metastatic renal cell ...

Roche reports good results in 2017

Commenting on the Group’s results, Roche CEO Severin Schwan said: “In 2017, we made significant progress with good growth in both divisions driven by newly launched medicines and tests. I am ...

FDA grants Breakthrough Therapy Designation for Roche’s balovaptan in autism spectrum disorder

Roche announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its investigational oral medicine balovaptan (previously known as RG7314), a ...

CHMP recommends EU approval of Roche’s Hemlibra for people with haemophilia A with inhibitors

Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Hemlibra® (emicizumab) for routine prophylaxis of bleeding episodes in ...

Invitation to Roche's Virtual Pipeline Event

We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Tuesday, 13 February 2018.

Reminder: Invitation to Roche's Full Year Results 2017 Presentation

Roche will publish its Full Year Results for 2017 prior to the opening of the Swiss Stock Exchange on Thursday, 1 February 2018.

TECENTRIQ approved in Japan for the treatment of unresectable, advanced or recurrent NSCLC

Roche’s OCREVUS (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis

Roche announced today that the European Commission (EC) has granted marketing authorisation for OCREVUS® (ocrelizumab) for patients with active relapsing forms of multiple sclerosis defined by ...

Roche commences tender offer for all shares of Ignyta, Inc. for US$ 27.00 per share in cash

Roche today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Ignyta, Inc. at a price of US$ 27.00 per share.

Invitation to Roche's Full Year Results 2017 Presentation

Roche will publish its Full Year Results for 2017 prior to the opening of the Swiss Stock Exchange on Thursday, 1 February 2018.

Roche and GE enter partnership to develop integrated digital diagnostics platform to improve oncology and critical care treatment

Roche announced today that it has entered into a strategic, long-term partnership with GE Healthcare in order to jointly develop and co-market digital clinical decision support solutions. The ...

Roche launches the cobas Plasma Separation Card to increase access to HIV testing for patients living in remote areas

Roche announced today the launch of the cobas® Plasma Separation Card. This new solution is a stable and easy-to-use sample collection device for HIV plasma viral load testing. By providing a small ...